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ABSTRACT: while investigators have a duty 
to provide research participants with summary find-
ings at the end of a study, providing general informa-
tion during the course of research is rarely considered. 
However, this raises an important ethical issue in the 
context of long-term studies such as cohorts or bio-
banks. We investigated this issue in the context of two 
ANRS cohorts of HIV-infected patients, AQUITAINE 
and COPILOTE. Face-to-face interviews were con-
ducted with HIV patient representatives and research 
professionals concerning the delivery of information 
in the course of the research. Respondents stated that 
participants wish to be informed of research results 
(both aggregate and individual) but also expect gen-
eral information about the cohort itself, research pro-
gression, and what their participation may provide. It 
was concluded that information provided during the 
course of the research may help participants to distin-
guish between care and research. The essential role of 
clinicians-investigators in providing information was 
emphasized.
KEY WORDS: cohort, information after inclusion, 
research participants, HIV, therapeutic misconception
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Providing research participants with summary results upon completion of a study has been recognized as an important ethical duty 
(World Medical Association, 2000; Council for 
International Organizations of Medical Sciences, 2002; 
Fernandez, Kodish, & Weijer, 2003; Knoppers et al., 2006). 
Empirical studies concerning communication of research 
results (reviewed by Shalowitz & Miller, 2008) have 
revealed the complexity of this issue in terms of the impact 
of research results, the distinction between aggregate and 
individual results, and the potential impact of the informa-
tion on participants, as well as barriers for investigators. 
Ongoing communication with study participants is 
rarely considered, although this issue is particularly 
relevant in the context of long-term studies where sum-
mary results may not be available for several years after 
the study begins. Such communication might occur 
through investigator-initiated newsletters (Moutel et al., 
2005; McCarty et al., 2011). Miller et al. (2011) recently 
reported on the importance of “non-results informa-
tion,” a practice developed by a number of genetics 
researchers whom they surveyed. McCarty et al. (2011) 
state that a newsletter in a population-based biobank can 
play a key role in maintaining trust, reminding people 
of their participation, and allowing participants to with-
draw in case of protocol changes. In a previous report, 
we also underlined the importance of providing infor-
mation to keep participants updated with research prog-
ress in a sub-study including a biobank (Moutel et al., 
2005). Giving information about the genetic markers to 
be studied during the progress of research was consid-
ered an important aspect of respecting participants and 
acknowledging the value of their samples. It was consid-
ered necessary to ensure that the initial informed con-
sent remained valid over time due to the various 
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intervening scientific choices made. Empirical support 
for this practice has been described in a study by Smith 
et al. (2011) that underlines the importance of keeping 
participants informed over time via “ongoing consent.” 
The purpose of this study was to learn about the atti-
tudes of patient representatives and research profession-
als concerning the value of ongoing communication in 
the context of two cohorts of HIV-infected patients. 
First, we chose to explore the opinion of patient advo-
cates within the TRT-5, a coalition of French HIV/AIDS 
organizations which has been working for years with the 
French Agence Nationale de Recherches sur le Sida et les 
hépatites virales (ANRS) to improve access to research 
information (Collard & Taéron, 2004; Moutel et al., 
2005). Second, we sought the perspectives of research 
professionals, including principal investigators, clini-
cians, and researchers. In this category, we included a 
representative of the research agency. Participants’ per-
spectives will be the object of a subsequent report. 
Method
Two cohorts were chosen for this study: AQUITAINE 
(Msellati et al., 1990) and APROCO-COPILOTE 
(COPILOTE) (Le Moing et al., 2002). Details of the 
cohorts are given in the supplementary online content 
(http://dx.doi.org/10.1525/jer.2011.6.4.76). 
As summarized in Table 1, the cohorts differ. 
AQUITAINE is an observational cohort based on follow-
up consultations in the southwest of France. COPILOTE 
is a multicenter study with follow-up consultations every 
four months including blood samples and self-
administered questionnaires. In AQUITAINE, informa-
tion is given to clinicians-investigators, who are invited 
every three months to a meeting at which both the proj-
ects and the results are discussed. Newsletters to partici-
pants have been developed in two sub-studies since 2009. 
In COPILOTE, information to both clinicians-investiga-
tors and participants exists since the study’s inception 
(COPILOTE being the continuation of the APROCO 
cohort). An annual newsletter dedicated to the participat-
ing physicians was coupled with a participant newsletter. 
This achieves two objectives: first, it informs the physi-
cians, and second, it allows the physicians to deliver the 
participant newsletter during a medical consultation.
Semi-directed Interviews
PoPulation interviewed
We investigated the opinions of three groups: (1) the 
coordinators of TRT-5 (Traitements & Recherche 
Thérapeutique 5) and of each of the eight associations 
comprising this coalition involved in HIV clinical 
research: Actions Traitements, Act Up-Paris,  Aides, 
Arcat, Dessine Moi Un Mouton, Nova Dona, Sida info 
Service, and Sol En Si; (2) three categories of profes-
sionals of AQUITAINE and COPILOTE (the principal 
investigators in charge of coordinating the project and 
who were involved in patient care, either directly or 
indirectly; clinicians involved in patient follow-up; and 
researchers not involved in clinical care); and (3) the 
Director of the ANRS, an agency that coordinates and 
Table 1. Context of the Study: aQuitaine and CoPilote Cohorts.
aQuitaine CoPilote
Inclusion 1987
Still including
HIV-positive individuals
1997–1999 (COPILOTE being the continuation of APROCO) 
Ended in 2009
HIV-positive individuals having started antiretroviral treatment 
Hospitals Southwest of France Multicenter
Objective Study of the natural history 
and undertreatment of HIV 
infection
Study of the factors associated with long-term treatments
Conditions for participants Data (standardized question-
naire) collected during each 
medical consultation or 
hospitalization 
Medical follow-up visits every four months
Blood sample taking
Questionnaires 
Information for clinicians/
investigators
Scientific meetings every  
three months on the cohort’s 
projects and results
Regular scientific meetings
10 newsletters from 1999–2009 (includes information about  
sub-studies)
Information for participants Newsletters since 2009 in two 
sub-studies including new 
consent
10 newsletters from 1999–2009 (includes information about  
sub-studies) delivered during consultation 
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funds research on AIDS and viral hepatitis in France 
and developing countries. 
The two coordinators of TRT-5, the cohort investigators 
of AQUITAINE and COPILOTE, and the Director of the 
ANRS were contacted during the first semester of 2009 by 
an e-mail describing the goal of the study and inviting them 
to a face-to-face interview. Their help was also requested to 
identify the resource persons to be interviewed in the asso-
ciations comprising TRT-5 and in both cohorts. Invitations 
were then sent by e-mail to each contact person. 
the interviewS
The interviews consisted of a series of questions 
designed to investigate the perception of the informa-
tion available to cohort participants after they began 
participation in the research. Most questions were 
designed so that an initial “yes or no” response was 
sought before comments. Specific modifications to 
some questions were made according to the category of 
respondents interviewed (as specified in the results).
data ColleCtion
The interviews (about 1–1/2 hours long) were conducted 
either in person or by telephone. In either case, respon-
dents were asked for their permission to record the inter-
view and the anonymity of their responses was assured. 
data analySiS
The recorded interviews were fully transcribed. Each 
respondent was assigned a number and the data were 
entered into Excel. Tables were created for each ques-
tion and for each category of respondents with their 
comments. A semi-quantitative analysis was performed 
according to the yes/no/other answers. The qualitative 
analysis was performed using a two-step procedure: (1) 
the ideas expressed by the respondents were identified 
and (2) the frequency of their occurrence was analyzed. 
Respondents’ quotes were selected based on their rele-
vance to the issue, independent of the frequency of 
occurrence of the idea expressed.
results
A total of 27 interviews were conducted. All members of 
the TRT-5 group (11 in total) participated, including the 
two coordinators and the heads of the HIV patients’ 
associations. Two associations did not participate due to 
a lack of a temporary representative to the TRT-5 or 
because no contact was established. Of 17 professionals 
contacted, 16 agreed to be interviewed: the principal 
investigator, two researchers, and four clinicians from 
the AQUITAINE cohort (seven total); the two principal 
investigators, two researchers, and four clinicians from 
the COPILOTE cohort (eight total); and a representative 
of the ANRS working in the service of HIV/AIDS clini-
cal and therapeutic research (designated by the Director 
of the ANRS). All respondents agreed to be recorded. 
The results and salient points raised by the respon-
dents during the interviews are presented below. 
Citations and expressions that were found relevant are 
presented in the supplementary online content.
Question 1: What information after inclusion?
To the question “Would you say that there is a lack of 
information to participants after their inclusion in a 
cohort?” a majority of patient representatives (9/11) 
answered “yes”. In their comments, some qualified the 
lack as huge or reported the term “laboratory speci-
mens” to express the feeling of participants. Others 
recognized that participants are not always interested in 
such information and that the situation is beginning to 
evolve. On the contrary, the two respondents who 
answered in the negative think that cohort participants 
are very well informed as compared to clinical trials.
The question was posed in a slightly different form to 
professionals: “Do you think that participants are waiting 
for information after their inclusion in a cohort?” Twelve 
out of 16 answered positively (5/7 of AQUITAINE, 6/8 
of COPILOTE, and the representative of the ANRS). The 
respondents expressed that this is patient-dependent and 
that they do not really know the exact nature of the infor-
mation expected. One of the COPILOTE professionals 
insisted on the importance to provide information 
“whether they ask for it or not,” the feedback demon-
strating respect toward participants.  
Four answered in the negative (2/7 of AQUITAINE, 2/8 
of COPILOTE). They mentioned lack of participant inter-
est in research in general and the fact that participants are 
mostly interested in information concerning themselves. 
They reported that participants lose the feeling of belong-
ing to a cohort after a while. One clinician stated that con-
sultation was the opportunity to provide a reminder of 
participation by showing the general data obtained thanks 
to their participation (through a web site in this example). 
Question 2: Have you ever had requests from people  
seeking information on the cohort in which they are 
participating?
Table 2 shows that only 9/27 reported receiving requests. 
There were none in AQUITAINE. Among patient 
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representatives, one commented that this was happen-
ing often, while others reported that this was rare or 
that the requests concerned clinical trials rather than 
cohorts. Most professionals of COPILOTE commented 
that the requests were rare or episodic, except for one 
professional who commented that such requests some-
times arose and stimulated further communication. 
The main reason given for lack of requests was the lack 
of contact with participants (the two researchers in each 
cohort and one of the principal investigators). The others 
indicated that participants’ requests mostly concerned 
clinical trials or cohort sub-studies. 
The question was asked in a slightly different form to 
the ANRS representative: “Do you know if participants 
in cohorts request additional information after their 
inclusion in the study?” The answer was positive due to 
the request coming directly from the patient representa-
tives with whom the institution works extensively. 
Question 3: What kind of information do you think that 
cohort participants would like to receive?
As shown in Table 3, the most cited items were the “char-
acteristics and life of the cohort” and “research results.” 
Patient representatives specified that information pro-
vided to participants about their cohort should contain 
basic elements concerning the cohort such as socio-
demographic features, number of participants, general 
criteria for inclusion, and studies conducted on the data 
collected. Professionals from both cohorts also insisted 
that such information should include factual elements, 
such as what happens in the cohort, as well as giving 
general information about the state of health and the 
evolution of the disease for the patients included. It 
should also mention the implications of their participation 
for progress in HIV research. The ANRS representative 
stated that the participants should be able to follow the 
life of the cohort through the periodic provision of infor-
mation. In addition, most patient representatives and 
professionals stated that participants expect both indi-
vidual and aggregate results, including research results 
from sub-studies and from samples they provided. 
Question 4: Do you think that, in most cases, the 
information you have mentioned is given to participants?
The three respondents who responded in Question 3 
that they did not know what type of information 
Table 2. have you ever had requests from people seeking information on the cohort  
in which they are participating? (Question 2)
Patient  
representatives
n=11
Professionals
total
n=27
aQuitaine 
Cohort
n=7
CoPilote 
Cohort
n=8
the  
representative 
of anrS
Yes 3 0 5 1 9
No 8 7 3 0 18
Table 3. what kind of information do you think that cohort participants would like to receive? Spontaneous terms cited by the 
interviewees (Question 3).
Patient  
representatives
n=11
Professionals
total
n=27
aQuitaine 
Cohort
n=7
CoPilote 
Cohort
n=8
the 
 representative 
of anrS
Characteristics and life 
of the cohort
8 4 2 1 15
Research results 5 2 7 1 15
Impact for follow-up 1 0 3 0 4
Benefits issued from 
participation
2 0 1 0 3
HIV research in general 0 2 1 0 3
Fate of the samples 2 0 1 0 3
No information wished 2 2 1 0 5
Do not know 1 1 1 0 3
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participants expected were not asked this question. As 
shown in Table 4, only 8/24 respondents thought that 
the type of information they mentioned in Question 3 
was effectively given to participants in most cases. The 
positive answers most frequently relied on the existence 
of the newsletter for participants in COPILOTE and on 
the existence of the newsletter for investigators allowing 
potential questions from the participants to be 
answered.
Among respondents who said that they did not think 
such information is typically provided, three categories 
of arguments were given:
1. Inadequate written information. The irregularity of 
the newsletter was mentioned as well as its lack of 
completeness and the failure of project administra-
tors to ask participants to evaluate the newsletter. 
One deplored the fact that information is provided 
only at the end of the trials. 
2. A lack of oral information. Patient representatives 
indicated that physicians do not always play their role 
in relaying research information, that they are not 
always informed about what is happening in the 
cohort, that they do not spend enough time delivering 
information to participants, that they do not explain 
in readily understood terminology, and that they rely 
on patient associations to provide information. One 
professional commented that it depends upon the 
good will of the physician. 
3. A lack of resources. One patient representative 
deplored the lack of budget to establish a telephone 
line or a web site. Professionals pointed to a lack of 
dedicated personnel and a lack of human skill with 
patient communication.
Question 5: Do you think that participants are able to 
make the distinction between their research participation 
and medical care?
As shown in Table 5, only 6/27 respondents thought that 
participants are able to make this distinction. This cate-
gory of respondents includes no patient representatives.  
The ability to make the distinction between research 
participation and medical care is linked (according to 
the respondents) to the existence of specific elements 
due to the research. Professionals cited such elements as 
signature of consent, regular follow-up visits, existence 
of sub-studies, blood sample taking, questionnaires, and 
the length of the participation. Professionals of 
COPILOTE reported the existence of more such ele-
ments as compared to those of AQUITAINE.
The difficulty in making the distinction between 
research participation and medical care is associated 
Table 4. do you think that, in most cases, the information you have mentioned is 
given to participants? (Question 4)
Patient  
representatives
n=10
Professionals
total*
n=24
aQuitaine 
Cohort
n=6
CoPilote 
Cohort
n=7
the 
representative 
of anrS
Yes 2 1 4 1 8
No 6 3 2 0 11
Do not know 2 2 1 0 5
* Those who answered that they did not know to Question 3 were not asked this question.
Table 5. do you think that participants are able to make the distinction between their 
research participation and medical care? (Question 5)
Patient 
 representatives
n=11
Professionals
total
n=27
aQuitaine 
Cohort
n=7
CoPilote 
Cohort
n=8
the  
representative 
of anrS
Yes 0 3 2 1 6
No 8 3 4 0 15
Patient dependent 1 1 2 0 4
Do not know 2 0 0 0 2
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with: (1) the non-interventional and observational 
nature of the research, (2) the fact that follow-up is part 
of the cohort, (3) the lack of specific elements asked of 
research participants, (4) failure of physicians to talk 
about research, (5) failure to receive any result from their 
participation, (6) participants forgetting that they belong 
to a cohort, and (7) care and research having long been 
confounded in the case of HIV. One respondent stated 
that patients sometimes wonder about the usefulness of 
their participation.
discussion
The results of this exploratory study support the value 
of providing general information to research partici-
pants in an ongoing process. Through the perspective 
of patient representatives and cohort professionals we 
interviewed, participants wish to receive research 
results (both aggregate and individual), general infor-
mation concerning the cohort in which they partici-
pate, and information regarding HIV research progress 
and what their participation may provide. Although 
our patient representative respondents deplored the 
lack of research information generally provided, some 
acknowledged the provision of information through 
the distribution of a newsletter. 
The results also reveal the importance of ongoing 
information in reminding individuals of their research 
participation. Most respondents stressed the difficulty 
that research participants have with distinguishing 
between care and research, a situation described by 
Appelbaum, Roth, and Lidz (1982) as a therapeutic mis-
conception. When research is mostly based on follow-
up, it is difficult for participants to know which part is 
research and which part is care. Such a situation in which 
the benefits and burdens associated with each situation 
are confused for research participants has been described 
by Lazovski et al. (2009). For the respondents, the ability 
to make the distinction is associated with the existence 
of specific elements linked to the research (such as 
signed consent) and the existence of information. In 
support of this, professionals of COPILOTE (where 
more elements of research and information exist for 
participants) report that they receive requests from 
participants about the cohort, whereas there was no 
report of such requests in AQUITAINE. However, pro-
fessionals of COPILOTE still think that it is difficult for 
participants to make the distinction between care and 
research. Interestingly, focus-group participants in a 
study by McCarty et al. (2011) suggested that each 
edition of the newsletter should remind participants of 
their enrollment in research. Our respondents also 
pointed out the essential role of physicians in reminding 
patients of their research participation. As examples of 
this, one professional reported, “perhaps I consider some 
exchanges spontaneous, although they actually originate 
from me,” and another took advantage of medical con-
sultations to remind patients that, “thanks to their par-
ticipation, they have a valuable global follow-up tool.” 
Confusion between care and research may explain 
one surprising result obtained in this study: the rarity 
of requests for information from the participants. 
Smith et al. (2011) found a similar absence of ques-
tions. They describe additional reasons (lack of oppor-
tunity, not knowing whom to ask) to explain this 
contradiction.
Finally, the respondents in this study insisted that 
expectations are quite participant dependent. This is not 
surprising as the heterogeneous nature of participants’ 
expectations regarding research information has been 
found in a number of studies (MacNeil & Fernandez, 
2006; Dixon-Woods et al., 2006; Murphy et al., 2008; 
Baret & Godard, 2011). While this may appear as a dif-
ficulty in the construction of information and in the 
generalization of the findings, this should not be an 
argument for evading the duty to inform. As stated by 
one professional in this study, it is important to inform 
whether they take the information or not. McCarty et al. 
(2011) recommended against an initial opt-out option 
for receiving the study newsletter in one’s consent form. 
They emphasized the need to provide study information 
to all participants after initial consent. 
The limitations of our approach lie in the small num-
ber of respondents in each category and in the qualitative 
interpretation of the data. The specific context of the 
study also makes the generalization of the results diffi-
cult. Given that cohort participation was based on long-
term medical follow-up has a number of implications in 
terms of the differentiation between the medical and 
research part of the activities. 
Best Practices
Our study supports the idea that general information 
about ongoing research should be made available to 
participants and that the delivery of this information 
should be encouraged as a measure of respect as well 
as to generate interest, awareness, and commitment to 
research. As shown in this study, the availability of 
general information stimulates physicians to commu-
nicate with participants about the ongoing research. It 
also is a way of thanking the participants, and helping 
them to grasp the distinction between medical care 
and research. 
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research agenda
There is a need for more studies on this issue with 
other disease entities, and in other cultural and 
national contexts. Furthermore, there is little evi-
dence-based guidance as to the kinds of general infor-
mation and  global research results that are meaningful 
for research participants. To what extent do partici-
pants want to know about how their participation 
contributes to a better understanding of their disease? 
What is their interest in the state of research on their 
disease, given that the pace at which knowledge 
advances may be very slow in relation to their hope for 
personal recovery? 
educational implications
When introducing students to the concept and opera-
tionalization of informed consent, concepts of ongoing 
provision of various types of information should also be 
explored in relation to various contexts of research.
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